Accordingly, either rapamycin treatment or AMPK-activation, by inhibiting mTORC1 and stimulating the autophagy machinery (Atg-1/Ulk), are shown to enhance Aβ clearance, reduce deposition, and abate pathology in transgenic AD mice [110, 192, 194–196]. The gene discussed is PRKAA1; the disease is Alzheimer disease.